Literature DB >> 16410150

Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples.

Ana B Baranda1, Rosa M Alonso, Rosa M Jiménez, Wolfgang Weinmann.   

Abstract

1,4-Dihydropyridines calcium channel antagonists (1,4-DHP CCAs) are photolabile and the products of their photodecomposition have no pharmaceutical activity. In our previous work we have presented a screening procedure for eleven 1,4-DHPs in plasma by LC-MS-MS using multiple reaction motoring. The laboratory process includes preparation and storage of stock solutions, plasma storage, solid-phase extraction, reconstitution of extracts and storage time in an autosampler for LC-MS-MS analysis. Prior to validation of the analytical procedure, we have tested the stability of these compounds by exposure to light. Methanolic solutions have been exposed to laboratory and UV light and the stability of the compounds in plasma was tested by exposure of spiked plasma samples to laboratory light at room temperature. Stability during freeze-thaw cycles and stability during 2 month storage at -20 degrees C have been tested as well. Products of photodecomposition have been identified after forced degradation and the degree of degradation has been quantified using LC-UV-DAD and LC-MS-MS, respectively. A 96% degradation after only 2h has been observed when solutions of nifedipine or nisoldipine were exposed to laboratory light in clear glass vials. In plasma samples degradation was 25% in only 2h for both compounds. The main degradation product was produced by oxidation of the dihydropyridinic ring resulting in the pyridine analogue that has been described as the first metabolite in the metabolic pathway. Only minor degradation was found for the other tested compounds after 2h light exposure in methanolic solutions. Furthermore, lercanidipine and nicardipine were also degradated by esterhydrolysis. Several additional minor degradation products were found for the other tested 1,4-DHPs, however, some of them could not be identified. Preconditions for storage and handling of plasma samples prior to and during analysis for 1,4-DHP CCAs are suggested in order to avoid photodecomposition of the analytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410150     DOI: 10.1016/j.forsciint.2004.11.014

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  6 in total

1.  Bio-activation of 4-alkyl analogs of 1,4-dihydropyridine mediated by cytochrome P450 enzymes.

Authors:  Xiao-Xi Li; Xiaoqian Zhang; Qing-Chuan Zheng; Yong Wang
Journal:  J Biol Inorg Chem       Date:  2015-03-18       Impact factor: 3.358

Review 2.  Recent Applications of the Multicomponent Synthesis for Bioactive Pyrazole Derivatives.

Authors:  Diana Becerra; Rodrigo Abonia; Juan-Carlos Castillo
Journal:  Molecules       Date:  2022-07-23       Impact factor: 4.927

3.  Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis.

Authors:  Sebastian Ewen; Markus R Meyer; Bodo Cremers; Ulrich Laufs; Andreas G Helfer; Dominik Linz; Ingrid Kindermann; Christian Ukena; Michel Burnier; Stefan Wagenpfeil; Hans H Maurer; Michael Böhm; Felix Mahfoud
Journal:  Clin Res Cardiol       Date:  2015-08-26       Impact factor: 5.460

4.  Quantitative determination of lercanidipine enantiomers in commercial formulations by capillary electrophoresis.

Authors:  Luciana Pereira Lourenço; Fernando Armani Aguiar; Anderson Rodrigo Moraes de Oliveira; Cristiane Masetto de Gaitani
Journal:  J Anal Methods Chem       Date:  2015-03-02       Impact factor: 2.193

5.  Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole.

Authors:  Eikan Mishima; Kazuichi Maruyama; Toru Nakazawa; Takaaki Abe; Sadayoshi Ito
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

6.  Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains.

Authors:  Ellen K Wasan; Jinying Zhao; Joshua Poteet; Munawar A Mohammed; Jaweria Syeda; Kevin Soulsbury; Jacqueline Cawthray; Amanda Bunyamin; Chi Zhang; Brian M Fahlman; Ed S Krol
Journal:  Pharmaceutics       Date:  2019-11-09       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.